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Dr John Elefteriades (New Haven, Conn). I congratulate the
authors on an outstanding paper on hybrid therapy for aortic arch
aneurysm. The number of patients is large, the follow-up is quite
complete, and the duration of follow-up is long. The mortality and
stroke rates are excellent. I do take issue with the underlying theme
of the paper, that a direct surgical approach to the aortic arch is to be
feared and avoided in favor of extra-anatomic and stent-graft1268 The Journal of Thoracic and Cardiovascular Surgery c Juntherapy. Direct approaches to the aortic arch are safe, durable, and
time tested. Many series, including our own recently presented ex-
perience, show stroke and mortality rates with the conventional ap-
proach that are very comparable with those in your presentation.
Also, our experience shows that the descending aorta is not com-
monly problematic, even in the long term, after successful type A
repair, raising doubt about whether adjunctive stent therapy in the
descending aorta is really necessary.
I have 3 questions. My first question has to do with early mortal-
ity. You list your hospital mortality as 3%, but by 6 months 19% of
the patients are dead. How did another 16% of the patients die within
6 months of hospital discharge? What was going on clinically and
radiographically with their aortas and their brains before death?
My second question has to do with anatomic morphology and se-
lection for operation. It appears that a large proportion of cases in
this paper are not really extended arch lesions, as the title indicates,
but rather typical type A and type B dissections. I am uncomfortable
with the classification of the large number of patients with chronic
type B dissection in this series as having ‘‘arch’’ lesions. Descending
dissections are nearly always limited to the region distal to the sub-
clavian artery. These lesions are well treated by a relatively straight-
forward resection via left thoracotomy on left atrial–femoral artery
bypass. With a clamp placed between the left carotid and left subcla-
vian arteries, one has excellent exposure for the proximal anastomo-
sis. Why did the authors classify these as arch lesions and perform
their complex extra-anatomic repair?
For the third question, let us consider the failures of therapy.
How do you explain the persistence or progressive enlargement of
the aneurysm in 25% of your patients?
Congratulations on an excellent presentation.
Dr Shimamura. Thank you, Dr Elefteriades, for your kind com-
ments and important questions.
Regarding the first question about mortality, the early mortality
included 3 patients with postoperative strokes, and we lost these 3
patients within 1 year. It could be said that we have lowered the qual-
ity of life of the patients postoperatively, but the death is not associ-
ated directly to the stent graft. Also, there is a patient who had an
fatal aortoesophageal fistula, as I showed in my slides. We lost
this patient after successful treatment for a ruptured aneurysm
however, this endoluminal treatment does not resect the whole aneu-
rysm, so this kind of problem needs more investigation. Most of the
late deaths are associated with the relatively high risk of the back-
ground of the patients. We introduced stent-graft treatment in
clinical use in 1993, and this is the very first in Japan. Many patients
with severe comorbidities were sent to our institution, and we have
to deal with these high-risk patients. This could explain the
relatively poor overall survival in the long term. However, we be-
lieve that avoidance of the aortic arch–related deaths is satisfactory.
Your second question concerned the indication for this proce-
dure. Yes, we include type B dissection for this procedure, but the
indication is only for the complication-specific treatment for type
B dissection. We undertook this procedure for the patient with
type B dissection who has a very proximal intimal tear near to the
subclavian artery. These tears cannot be treated with endovascular
repair. Of course, there are options to do graft replacement with
a left thoracotomy, but we think that closure of the intimal tear via
a median approach is compatible with this treatment, and the results
are satisfactory in our study.e 2008
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CDRegarding the third question, the majority of the aneurysms have
an extension distally, and it was thought to be difficult to treat that
extension with conventional treatment via a median sternotomy.
Our series contains about 20% of patients who have a relatively prox-
imal location of the distal end of the aneurysms, and these could be
treated with traditional surgical repair. However, this procedure has
an advantage even in these aneurysms, because with the stent graft
you can alternate your distal anastomosis and manipulate only in the
proximal arch. This could be a very easy way to control the bleeding.
Dr BruceW. Lytle (Cleveland, Ohio).Regardless of the specific
indications for how often you do a debranching or whether this is
just an extension of a conventional arch repair, the concept of put-
ting in a stent graft during an open aortic operation, perhaps to
extend it to the descending aorta, makes a lot of sense. We certainly
have tried to do this. One of the things I have been really disap-
pointed in is the lack of response of our industrial partners to thisThe Journal of Thoraissue. We have tried to get a number of the companies interested
in making devices specifically for the purpose of being put in at
the time of surgery. They just cannot seem to get this.
The way you wrap the string around the graft is very clever, but
are you still doing it that way after 14 years? Has there not been
some company that has agreed to manufacture that on sort of
a prospective basis?
Dr Shimamura. We do not use the sheath to deliver the stent
graft, but we have no company that makes this kind of commercially
available stent graft. I hear that that kind of device is available in
Germany, and I think the production of such a device could expand
this technique widely.
Dr Lytle. I invite our colleagues to help our industrial partners to
understand that we are interested in this, because regardless of the
specific indication, there is no doubt that this concept will have
some degree of usefulness.cic and Cardiovascular Surgery c Volume 135, Number 6 1269
